SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools announced a definitive agreement to sell its…

STANDARD BIOTOOLS INC. · 425 filed Oct 5, 2026 at 16:17 ET

At the news

NEUTRALIMPACT 5/10

425 filed Oct 5, 2026 at 16:17 ET

Standard BioTools announced a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days, subject to customary closing conditions. This follows the recent termination of the Multiplex Bio deal and the signing of the Element Biosystems agreement for the Mass Cytometry business, continuing the company's strategic divestiture process.

  • Standard BioTools entered into a definitive agreement to sell its Microfluidics business to ARCHIMED.
  • Transaction expected to close in approximately 30 days, subject to customary closing conditions.
  • No purchase price or financial terms disclosed in the filing.
  • This is the second business divestiture announced within a week, following the Element Biosystems deal for the Mass Cytometry business.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access